July 24, 2023 05:08 AM EDTUpdated 06:21 AM
Pharma

Phar­ma earn­ings sea­son starts with cor­po­rate prof­its, new CEOs tak­ing cen­ter stage

Andrew Dunn

Senior Biopharma Correspondent

Quar­ter­ly earn­ings kick off in earnest this week, with a hand­ful of the largest bio­phar­ma com­pa­nies set to re­port how they’re do­ing mid­way through 2023 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times